Personalis' (PSNL) "Buy" Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright has reaffirmed a "buy" rating for Personalis' stock (NASDAQ:PSNL) with a target price of $8.50, indicating a potential upside of 62.21% from the previous close.
• Personalis recently reported a quarterly EPS of ($0.23), which exceeded analysts' expectations, but its revenue was $17.20 million, falling short of the $20.12 million forecast.
• Institutional investors hold a significant portion of Personalis' stock, with hedge funds and other entities owning 61.91% of the company, reflecting strong interest from large investors.

HC Wainwright reissued their buy rating on shares of Personalis (NASDAQ:PSNL - Free Report) in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a $8.50 price target on the stock.

A number of other research firms have also commented on PSNL. Wall Street Zen lowered Personalis from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Guggenheim began coverage on Personalis in a research note on Thursday, May 15th. They set a "buy" rating and a $6.00 price objective on the stock. Finally, BTIG Research set a $6.00 price objective on Personalis in a research note on Wednesday, August 6th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $7.42.

Personalis Price Performance

Personalis stock traded down $0.25 during trading hours on Monday, hitting $5.85. The stock had a trading volume of 1,006,825 shares, compared to its average volume of 830,451. The stock has a market capitalization of $518.76 million, a price-to-earnings ratio of -4.57 and a beta of 1.76. Personalis has a 1-year low of $2.83 and a 1-year high of $7.79. The stock's fifty day moving average is $5.50 and its two-hundred day moving average is $4.86.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $20.12 million. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts anticipate that Personalis will post -1.4 EPS for the current year.

Hedge Funds Weigh In On Personalis

Large investors have recently added to or reduced their stakes in the business. American Century Companies Inc. lifted its position in Personalis by 33.9% during the first quarter. American Century Companies Inc. now owns 67,377 shares of the company's stock worth $236,000 after buying an additional 17,056 shares during the period. Dimensional Fund Advisors LP lifted its position in Personalis by 144.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company's stock worth $2,372,000 after buying an additional 242,141 shares during the period. Two Sigma Advisers LP lifted its position in Personalis by 25.6% during the fourth quarter. Two Sigma Advisers LP now owns 34,300 shares of the company's stock worth $198,000 after buying an additional 7,000 shares during the period. Trexquant Investment LP lifted its position in Personalis by 455.0% during the first quarter. Trexquant Investment LP now owns 122,959 shares of the company's stock worth $432,000 after buying an additional 100,804 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in Personalis by 53,126.7% during the fourth quarter. BNP Paribas Financial Markets now owns 71,856 shares of the company's stock worth $415,000 after buying an additional 71,721 shares during the period. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.